Therapeutic | Rozanolixizumab |
Target | FCGRT |
Heavy Chain | EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK |
100% seqID Fv Structure | 6fgb [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6fgb [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | UCB |
Conditions Approved | na |
Conditions Active | Chronic inflammatory demyelinating polyradiculoneuropathy, Idiopathic thrombocytopenic purpura, Myasthenia gravis |
Conditions Discontinued | Immunological disorders |
Notes |